KIDNEY DAMAGE AND BROKEN BONES FOR HIV-POSITIVE PATIENTS

IMPORTANT CLIENT UPDATES - CLICK LINKS BELOW:

Eiland & Bonnin are representing over 600 clients in a lawsuit against Gilead Sciences Inc., the makers of commonly used antiviral therapy used to treat HIV.  Since the early 2000s Gilead has sold an antiviral drug called Tenofovir Disoproxil Fumarate (TDF).  TDF has well known side effects including kidney damage and bone loss, of which the company was aware, and about which they warned doctors and patients.

However, the lawsuit alleges that also in the early 2000s, Gilead discovered an alternative drug, called TAF, that could be used at a much lower dose and which, accordingly, would be safer for kidney and bones.  We allege that instead of putting TAF on the market, Gilead intentionally withheld that safer version of its drug from patients in order to completely wring all profits from TDF first, rather than have TAF replace or “cannibalize” (to use the company’s term) TDF’s blockbuster sales.  Our experts advise us that Gilead’s withholding of TAF for nearly a decade resulted in billions of dollars of additional profit to the company while putting thousands of patients at unnecessary risk of kidney damage and/or bone loss.

We believe that individuals who have taken TDF and suffered from its side effects that could have been prevented by using TAF instead deserve to be compensated by the company for their suffering.